Cognitive · Research Phase
N-acetyl Semax Amidate
No lawful US pathway
01 · Overview
N-acetyl Semax Amidate is a modified form of Semax, a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) combining the ACTH 4-7 sequence with a C-terminal Pro-Gly-Pro tripeptide (PMID 27586814). The N-terminal acetylation and C-terminal amidation are intended to increase resistance to enzymatic breakdown, and the proteolytic stability of acetylated Semax has been examined in biological media (PMID 23652441).
In a neuroblastoma cell study, however, acetylation changed Semax's metal-binding chemistry and removed its protection against copper-induced toxicity (PMID 27586814). Claims of enhanced brain penetration or prolonged activity for this analog have not been demonstrated in published studies.
02 · Research summary & key findings
Published research on the acetylated and amidated form is limited to in vitro chemistry and stability work; no animal efficacy or human clinical studies of this specific analog were found in PubMed. Evidence for the parent peptide Semax includes rat studies showing that a single intranasal dose rapidly increased BDNF and NGF gene expression in the hippocampus (PMID 17353092), and a Russian study of 110 ischemic stroke patients reporting higher plasma BDNF and better functional recovery scores with Semax plus rehabilitation (PMID 29798983). These parent-compound findings cannot be assumed to apply to the modified analog.
03 · Regulatory status
N-acetyl Semax Amidate is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
No lawful pathway today
N-acetyl Semax Amidate is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for cognitive support?
N-acetyl Semax Amidate is a research compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on cognitive support, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Intranasal
- Subcutaneous injection
References
- [1]Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10 Neurosci Lett, 2007. PMID 17353092
- [2]Stability of Semax acetyl to proteolysis in various biological media Dokl Biol Sci, 2013. PMID 23652441
- [3]Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties J Inorg Biochem, 2016. PMID 27586814
- [4][The efficacy of semax in the tretament of patients at different stages of ischemic stroke] Zh Nevrol Psikhiatr Im S S Korsakova, 2018. PMID 29798983
Primary literature
- PubMed: "N-acetyl Semax Amidate"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "N-acetyl Semax Amidate"
Registered interventional and observational studies, including status and phase.
- PubChem: "N-acetyl Semax Amidate"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Cognitive
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.